Inmunómica traslacional en neoplasias hematológicas
Hospital Clinic Barcelona
Barcelona, EspañaHospital Clinic Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (169)
2024
-
Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch
Transplantation, Vol. 108, Núm. 3, pp. 787-801
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Haematologica, Vol. 109, Núm. 3, pp. 877-887
-
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection
Haematologica, Vol. 109, Núm. 6, pp. 1909-1917
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2023
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311
2022
-
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism
Cancers, Vol. 14, Núm. 17
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710
-
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Blood Advances, Vol. 6, Núm. 2, pp. 690-703
-
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
European Journal of Cancer, Vol. 174, pp. 243-250
-
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
ESMO Open, Vol. 7, Núm. 2
-
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239
-
Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting
Cancers, Vol. 14, Núm. 18
-
Multidisciplinary Consensus for the Management of Pulmonary Thromboembolism
Archivos de Bronconeumologia